Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Proteome Sciences ( (GB:PRM) ) just unveiled an announcement.
Proteome Sciences has secured a significant contract with a US biopharmaceutical company to provide mass spectrometry services for a clinical trial, valued at over $1 million. This agreement, which utilizes their GCLP accreditation, is expected to be largely fulfilled within the current financial year and into 2026, demonstrating the company’s growing demand in the US and Europe for its specialized services.
More about Proteome Sciences
Proteome Sciences is a company in the biotechnology industry, specializing in mass spectrometry services. The company focuses on providing analytical services to the biopharmaceutical sector, with a market focus on clinical trials and drug performance monitoring.
YTD Price Performance: 32.06%
Average Trading Volume: 169,388
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £13.25M
For detailed information about PRM stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue